Clinical characteristics of the 12 patients with myelodysplastic syndrome
| Patient no. . | Age at diagnosis of AA, y . | Severity of AA at diagnosis . | Previous therapies . | Response to treatment after 6 mo . | Cumulative dose of G-CSF, mg/kg . | No. of days of G-CSF therapy . | Duration of AA to MDS, mo . | Karyotype . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | Severe | None | NR | 0 | 0 | 9 | − 7 | Alive (BMT) |
| 2 | 12 | Moderate | None | NR | 0.4 | 50 | 11 | + 11 | Alive (BMT) |
| 3 | 7 | Severe | None | PR | 1.1 | 100 | 62 | + 9 | Alive |
| 4 | 10 | Very severe | None | NR | 4.1 | 300 | 17 | − 7 | Dead |
| 5 | 10 | Moderate | HDMP, CyA, AND | NR | 0.2 | 21 | 66 | del(11)(9?:14) | Dead |
| 6 | 12 | Severe | HDMP, DAN, G-CSF | NR | 0.8 | 955 | 39 | − 7 | Dead |
| 7 | 2 | Severe | CyA, G-CSF | NR | 0.9 | 1125 | 40 | + 9q | Dead |
| 8 | 9 | Severe | HDMP, CyA, G-CSF | NR | 8.7 | 665 | 21 | − 7 | Dead |
| 9 | 17 | Severe | ATG, HDMP, AND, G-CSF | NR | 2.2 | 277 | 21 | − 7 | Dead |
| 10 | 9 | Moderate | HDMP, AND | NR | 3.7 | 824 | 40 | − 7, + 21 | Dead |
| 11 | 9 | Severe | HDMP, CyA | PR | 4.1 | 330 | 81 | − 7 | Dead |
| 12 | 2 | Very severe | None | PR | 7.4 | 839 | 37 | + 7q | Dead |
| Patient no. . | Age at diagnosis of AA, y . | Severity of AA at diagnosis . | Previous therapies . | Response to treatment after 6 mo . | Cumulative dose of G-CSF, mg/kg . | No. of days of G-CSF therapy . | Duration of AA to MDS, mo . | Karyotype . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | Severe | None | NR | 0 | 0 | 9 | − 7 | Alive (BMT) |
| 2 | 12 | Moderate | None | NR | 0.4 | 50 | 11 | + 11 | Alive (BMT) |
| 3 | 7 | Severe | None | PR | 1.1 | 100 | 62 | + 9 | Alive |
| 4 | 10 | Very severe | None | NR | 4.1 | 300 | 17 | − 7 | Dead |
| 5 | 10 | Moderate | HDMP, CyA, AND | NR | 0.2 | 21 | 66 | del(11)(9?:14) | Dead |
| 6 | 12 | Severe | HDMP, DAN, G-CSF | NR | 0.8 | 955 | 39 | − 7 | Dead |
| 7 | 2 | Severe | CyA, G-CSF | NR | 0.9 | 1125 | 40 | + 9q | Dead |
| 8 | 9 | Severe | HDMP, CyA, G-CSF | NR | 8.7 | 665 | 21 | − 7 | Dead |
| 9 | 17 | Severe | ATG, HDMP, AND, G-CSF | NR | 2.2 | 277 | 21 | − 7 | Dead |
| 10 | 9 | Moderate | HDMP, AND | NR | 3.7 | 824 | 40 | − 7, + 21 | Dead |
| 11 | 9 | Severe | HDMP, CyA | PR | 4.1 | 330 | 81 | − 7 | Dead |
| 12 | 2 | Very severe | None | PR | 7.4 | 839 | 37 | + 7q | Dead |
AA indicates aplastic anemia; G-CSF, granulocyte colony-stimulating factor; MDS, myelodysplastic syndrome; BMT, bone marrow transplantation; HDMP, high-dose methylprednisolone; CyA, cyclosporin; AND, androgen; DAN, danazol; NR, no response; and PR, partial response.